FRANCISCO JAVIER
LÓPEZ LONGO
Ikertzailea 2019-(e)ra arte
![Foto de FRANCISCO JAVIER](/img/nophoto.png)
![Foto de Hospital Universitario Central de Asturias](/img/noimage_org.png)
Hospital Universitario Central de Asturias
Oviedo, EspañaHospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (17)
2022
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
2021
-
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360
2018
-
Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 584-601
2016
-
Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment
Archivos de Bronconeumologia, Vol. 52, Núm. 1, pp. 36-45
-
LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition
Clinical and Experimental Rheumatology
2015
-
Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis
Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35
-
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain
Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640
2014
-
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility
Arthritis Research and Therapy, Vol. 16, Núm. 1
2013
-
Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility
Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238
2012
-
Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
Arthritis Research and Therapy, Vol. 14, Núm. 3
-
Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis
Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279
-
Influence of the IL6 gene in susceptibility to systemic sclerosis
Journal of Rheumatology, Vol. 39, Núm. 12, pp. 2294-2302
2011
-
No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis
Clinical and Experimental Rheumatology
2006
-
Registrolesaf. Características de los pacientes con lupus eritematoso sistémico síndrome antifosfolipídico registrados por usuarios médicos especialistas en reumatología y medicina interna
Reumatologia Clinica, Vol. 2, Núm. 3, pp. 131-136